| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | NEUTRAL | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 5.55▼ | 5.55▼ | 5.64▼ | 5.53▼ | 5.48▲ |
| MA10 | 5.72▼ | 5.70▼ | 5.68▼ | 5.44▲ | 4.76▲ |
| MA20 | 5.65▼ | 5.55▼ | 5.54▼ | 5.50▲ | 2.74▲ |
| MA50 | 5.68▼ | 5.30▲ | 5.00▲ | 4.07▲ | 1.80▲ |
| MA100 | 3.26▲ | 3.00▲ | 2.84▲ | 2.41▲ | 1.55▲ |
| MA200 | 1.96▲ | 1.85▲ | 1.79▲ | 1.78▲ | 5.86▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.071▼ | -0.072▼ | -0.073▼ | -0.109▼ | 0.363▲ |
| RSI | 49.768▼ | 51.739▲ | 52.518▲ | 55.586▲ | 73.616▲ |
| STOCH | 16.299▼ | 23.750 | 40.417 | 48.341 | 75.946 |
| WILL %R | -91.667▼ | -91.667▼ | -74.830 | -59.559 | -24.672▲ |
| CCI | -87.753 | -62.281 | -46.447 | 18.245 | 59.712 |
|
Wednesday, September 10, 2025 05:42 AM
SAN DIEGO, CA / ACCESS Newswire / September 10, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today ...
|
|
Wednesday, September 10, 2025 05:20 AM
Dermata Therapeutics (DRMA) announced a strategic pivot to prioritize the development and distribution of over-the-counter pharmaceutical ...
|
|
Wednesday, September 10, 2025 05:20 AM
As part of the Company’s strategic shift into the OTC marketplace, it has withdrawn its investigational new drug application for XYNGARI with FDA.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 17/09/25 | 5.72 | 5.72 | 5.47 | 5.52 | 75,215 |
| 16/09/25 | 5.615 | 6.225 | 5.54 | 5.905 | 139,300 |
| 15/09/25 | 5.60 | 5.69 | 5.27 | 5.43 | 117,060 |
| 12/09/25 | 5.298 | 5.70 | 5.285 | 5.405 | 22,700 |
| 11/09/25 | 5.50 | 5.72 | 5.40 | 5.40 | 36,600 |
| 10/09/25 | 5.50 | 5.739 | 5.25 | 5.50 | 78,500 |
| 09/09/25 | 5.455 | 5.495 | 5.0413 | 5.19 | 47,189 |
| 08/09/25 | 5.30 | 5.4396 | 5.25 | 5.26 | 8,726 |
| 05/09/25 | 5.58 | 5.62 | 5.2229 | 5.2569 | 14,195 |
| 04/09/25 | 5.90 | 5.93 | 5.40 | 5.50 | 47,400 |
|
|
||||
|
|
||||
|
|